Schanz, Julie

[["dc.bibliographiccitation.firstpage","73483"],["dc.bibliographiccitation.issue","43"],["dc.bibliographiccitation.journal","Oncotarget"],["dc.bibliographiccitation.lastpage","73500"],["dc.bibliographiccitation.volume","8"],["dc.contributor.author","Valent, Peter"],["dc.contributor.author","Orazi, Attilio"],["dc.contributor.author","Steensma, David P."],["dc.contributor.author","Ebert, Benjamin L."],["dc.contributor.author","Haase, Detlef"],["dc.contributor.author","Malcovati, Luca"],["dc.contributor.author","van de Loosdrecht, Arjan A."],["dc.contributor.author","Haferlach, Torsten"],["dc.contributor.author","Westers, Theresia M."],["dc.contributor.author","Wells, Denise A."],["dc.contributor.author","Giagounidis, Aristoteles"],["dc.contributor.author","Loken, Michael"],["dc.contributor.author","Orfao, Alberto"],["dc.contributor.author","Lübbert, Michael"],["dc.contributor.author","Ganser, Arnold"],["dc.contributor.author","Hofmann, Wolf-Karsten"],["dc.contributor.author","Ogata, Kiyoyuki"],["dc.contributor.author","Schanz, Julie"],["dc.contributor.author","Béné, Marie C."],["dc.contributor.author","Hoermann, Gregor"],["dc.contributor.author","Sperr, Wolfgang R."],["dc.contributor.author","Sotlar, Karl"],["dc.contributor.author","Bettelheim, Peter"],["dc.contributor.author","Stauder, Reinhard"],["dc.contributor.author","Pfeilstöcker, Michael"],["dc.contributor.author","Horny, Hans-Peter"],["dc.contributor.author","Germing, Ulrich"],["dc.contributor.author","Greenberg, Peter"],["dc.contributor.author","Bennett, John M."],["dc.date.accessioned","2019-12-17T12:21:04Z"],["dc.date.accessioned","2021-10-27T13:21:59Z"],["dc.date.available","2019-12-17T12:21:04Z"],["dc.date.available","2021-10-27T13:21:59Z"],["dc.date.issued","2017"],["dc.description.abstract","Myelodysplastic syndromes (MDS) comprise a heterogeneous group of myeloid neoplasms characterized by peripheral cytopenia, dysplasia, and a variable clinical course with about 30% risk to transform to secondary acute myeloid leukemia (AML). In the past 15 years, diagnostic evaluations, prognostication, and treatment of MDS have improved substantially. However, with the discovery of molecular markers and advent of novel targeted therapies, new challenges have emerged in the complex field of MDS. For example, MDS-related molecular lesions may be detectable in healthy individuals and increase in prevalence with age. Other patients exhibit persistent cytopenia of unknown etiology without dysplasia. Although these conditions are potential pre-phases of MDS they may also transform into other bone marrow neoplasms. Recently identified molecular, cytogenetic, and flow-based parameters may add in the delineation and prognostication of these conditions. However, no generally accepted integrated classification and no related criteria are as yet available. In an attempt to address this challenge, an international consensus group discussed these issues in a working conference in July 2016. The outcomes of this conference are summarized in the present article which includes criteria and a proposal for the classification of pre-MDS conditions as well as updated minimal diagnostic criteria of MDS. Moreover, we propose diagnostic standards to delineate between ´normal´, pre-MDS, and MDS. These standards and criteria should facilitate diagnostic and prognostic evaluations in clinical studies as well as in clinical practice."],["dc.identifier.doi","10.18632/oncotarget.19008"],["dc.identifier.eissn","1949-2553"],["dc.identifier.pmid","29088721"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/17006"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/92060"],["dc.language.iso","en"],["dc.notes.intern","Migrated from goescholar"],["dc.relation.eissn","1949-2553"],["dc.relation.orgunit","Universitätsmedizin Göttingen"],["dc.rights","CC BY 3.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/3.0"],["dc.subject.ddc","610"],["dc.title","Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","205"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","Haematologica"],["dc.bibliographiccitation.lastpage","213"],["dc.bibliographiccitation.volume","100"],["dc.contributor.author","Braulke, Friederike"],["dc.contributor.author","Platzbecker, Uwe"],["dc.contributor.author","Müller-Thomas, Catharina"],["dc.contributor.author","Götze, Katharina"],["dc.contributor.author","Germing, Ulrich"],["dc.contributor.author","Brümmendorf, Tim H."],["dc.contributor.author","Nolte, Florian"],["dc.contributor.author","Hofmann, Wolf-Karsten"],["dc.contributor.author","Giagounidis, Aristoteles A. N."],["dc.contributor.author","Lübbert, Michael"],["dc.contributor.author","Greenberg, Peter L."],["dc.contributor.author","Bennett, John M."],["dc.contributor.author","Solé, Francesc"],["dc.contributor.author","Mallo, Mar"],["dc.contributor.author","Slovak, Marilyn L."],["dc.contributor.author","Ohyashiki, Kazuma"],["dc.contributor.author","Le Beau, Michelle M."],["dc.contributor.author","Tüchler, Heinz"],["dc.contributor.author","Pfeilstöcker, Michael"],["dc.contributor.author","Nösslinger, Thomas"],["dc.contributor.author","Hildebrandt, Barbara"],["dc.contributor.author","Shirneshan, Katayoon"],["dc.contributor.author","Aul, Carlo"],["dc.contributor.author","Stauder, Reinhard"],["dc.contributor.author","Sperr, Wolfgang R."],["dc.contributor.author","Valent, Peter"],["dc.contributor.author","Fonatsch, Christa"],["dc.contributor.author","Trümper, Lorenz"],["dc.contributor.author","Haase, Detlef"],["dc.contributor.author","Schanz, Julie"],["dc.date.accessioned","2019-07-09T11:41:10Z"],["dc.date.available","2019-07-09T11:41:10Z"],["dc.date.issued","2015-02-01"],["dc.description.abstract","International Prognostic Scoring Systems are used to determine the individual risk profile of myelodysplastic syndrome patients. For the assessment of International Prognostic Scoring Systems, an adequate chromosome banding analysis of the bone marrow is essential. Cytogenetic information is not available for a substantial number of patients (5%-20%) with dry marrow or an insufficient number of metaphase cells. For these patients, a valid risk classification is impossible. In the study presented here, the International Prognostic Scoring Systems were validated based on fluorescence in situ hybridization analyses using extended probe panels applied to cluster of differentiation 34 positive (CD34(+)) peripheral blood cells of 328 MDS patients of our prospective multicenter German diagnostic study and compared to chromosome banding results of 2902 previously published patients with myelodysplastic syndromes. For cytogenetic risk classification by fluorescence in situ hybridization analyses of CD34(+) peripheral blood cells, the groups differed significantly for overall and leukemia-free survival by uni- and multivariate analyses without discrepancies between treated and untreated patients. Including cytogenetic data of fluorescence in situ hybridization analyses of peripheral CD34(+) blood cells (instead of bone marrow banding analysis) into the complete International Prognostic Scoring System assessment, the prognostic risk groups separated significantly for overall and leukemia-free survival. Our data show that a reliable stratification to the risk groups of the International Prognostic Scoring Systems is possible from peripheral blood in patients with missing chromosome banding analysis by using a comprehensive probe panel (clinicaltrials.gov identifier:01355913)."],["dc.identifier.doi","10.3324/haematol.2014.110452"],["dc.identifier.pmid","25344522"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/11765"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/58365"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.relation.issn","1592-8721"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Validation of cytogenetic risk groups according to International Prognostic Scoring Systems by peripheral blood CD34+FISH: results from a German diagnostic study in comparison with an international control group."],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","2239"],["dc.bibliographiccitation.issue","10"],["dc.bibliographiccitation.journal","Viruses"],["dc.bibliographiccitation.volume","14"],["dc.contributor.affiliation","Dierks, Sascha; 1Department of Clinical Chemistry, University Medical Center Göttingen, 37075 Göttingen, Germany"],["dc.contributor.affiliation","Thiele, Karin; 1Department of Clinical Chemistry, University Medical Center Göttingen, 37075 Göttingen, Germany"],["dc.contributor.affiliation","Bohne, Wolfgang; 2Interdisciplinary UMG Laboratory, University Medical Center Göttingen, 37075 Göttingen, Germany"],["dc.contributor.affiliation","Lugert, Raimond; 2Interdisciplinary UMG Laboratory, University Medical Center Göttingen, 37075 Göttingen, Germany"],["dc.contributor.affiliation","Weig, Michael; 2Interdisciplinary UMG Laboratory, University Medical Center Göttingen, 37075 Göttingen, Germany"],["dc.contributor.affiliation","Groß, Uwe; 2Interdisciplinary UMG Laboratory, University Medical Center Göttingen, 37075 Göttingen, Germany"],["dc.contributor.affiliation","von Ahsen, Nicolas; 1Department of Clinical Chemistry, University Medical Center Göttingen, 37075 Göttingen, Germany"],["dc.contributor.affiliation","Schanz, Julie; 1Department of Clinical Chemistry, University Medical Center Göttingen, 37075 Göttingen, Germany"],["dc.contributor.affiliation","Fischer, Andreas; 1Department of Clinical Chemistry, University Medical Center Göttingen, 37075 Göttingen, Germany"],["dc.contributor.affiliation","Schnelle, Moritz; 1Department of Clinical Chemistry, University Medical Center Göttingen, 37075 Göttingen, Germany"],["dc.contributor.author","Dierks, Sascha"],["dc.contributor.author","Thiele, Karin"],["dc.contributor.author","Bohne, Wolfgang"],["dc.contributor.author","Lugert, Raimond"],["dc.contributor.author","Weig, Michael"],["dc.contributor.author","Groß, Uwe"],["dc.contributor.author","von Ahsen, Nicolas"],["dc.contributor.author","Schanz, Julie"],["dc.contributor.author","Fischer, Andreas"],["dc.contributor.author","Schnelle, Moritz"],["dc.date.accessioned","2022-12-01T08:31:48Z"],["dc.date.available","2022-12-01T08:31:48Z"],["dc.date.issued","2022"],["dc.date.updated","2022-11-11T13:11:59Z"],["dc.description.abstract","In SARS-CoV-2 diagnostics, cycle threshold (Ct) values from qRT-PCRs semi-quantitatively estimate a patient’s viral load. However, relevant analytical differences between qRT-PCR assays are often neglected. This study was designed (i) to identify such differences between five commonly used assays and (ii) to demonstrate a straightforward strategy to harmonize them. QRT-PCRs for SARS-CoV-2 were carried out in 85 oropharyngeal swab samples using three fully automated (Alinity m, cobas®6800 and GeneXpert) and two semi-automated (genesig® and RIDA®GENE) assays. Qualitative results (positive/negative) showed excellent comparability between the fully automated assays, but not between the Alinity m and semi-automated methods. Ct values significantly varied between all the methods, with the median values ranging from 22.76 (Alinity m) to 30.89 (RIDA®GENE) and 31.50 (genesig®), indicating the lowest sensitivity for semi-automated methods. Passing–Bablok analysis further revealed systemic biases. Assay-specific viral load concentration calculations—based on generated individual standard curves—resulted in much better comparability between the assays. Applying these calculations, significant differences were no longer detectable. This study highlights relevant analytical differences between SARS-CoV-2 qRT-PCR assays, leading to divergent decisions about the mandatory isolation of infected individuals. Secondly, we propose a strategy to harmonize qRT-PCR assays to achieve better comparability. Our findings are of particular interest for laboratories utilizing different assays."],["dc.description.sponsorship","VolkswagenStiftung"],["dc.description.sponsorship","Open-Access-Publikationsfonds 2022"],["dc.identifier.doi","10.3390/v14102239"],["dc.identifier.pii","v14102239"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/118269"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-621"],["dc.relation.eissn","1999-4915"],["dc.rights","CC BY 4.0"],["dc.title","Comparison and Harmonization of Different Semi-Automated and Automated qRT-PCR Assays in the Assessment of SARS-CoV-2"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","unpublished"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","e2015034"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Mediterranean Journal of Hematology and Infectious Diseases"],["dc.bibliographiccitation.volume","7"],["dc.contributor.author","Bacher, Ulrike"],["dc.contributor.author","Schanz, Julie"],["dc.contributor.author","Braulke, Friederike"],["dc.contributor.author","Haase, Detlef"],["dc.date.accessioned","2016-08-22T12:41:23Z"],["dc.date.accessioned","2021-10-27T13:20:38Z"],["dc.date.available","2016-08-22T12:41:23Z"],["dc.date.available","2021-10-27T13:20:38Z"],["dc.date.issued","2015"],["dc.description.abstract","The karyotype represents one of the main cornerstones for the International Prognostic Scoring System (IPSS) and the revised IPSS-R (IPSS-R) that are most widely used for prognostication in patients with myelodysplastic syndromes (MDS). The most frequent cytogenetic abnormalities in MDS, i.e. del(5q), -7/del(7q), +8, complex karyotypes, or -Y have been extensively explored for their prognostic impact. The IPSS-R also considers some less frequent abnormalities such as del(11q), isochromosome 17, +19, or 3q abnormalities. However, more than 600 different cytogenetic categories had been identified in a previous MDS study. This review aims to focus interest on selected rare cytogenetic abnormalities in patients with MDS. Examples are numerical gains of the chromosomes 11 (indicating rapid progression), of chromosome 14 or 14q (prognostically intermediate to favorable), -X (in females, with an intermediate prognosis), or numerical abnormalities of chromosome 21. Structural abnormalities are also considered, e.g. del(13q) that is associated with bone marrow failure syndromes and favorable response to immunosuppressive therapy. These and other rare cytogenetic abnormalities should be integrated into existing prognostication systems such as the IPSS-R. However, due to the very low number of cases, this is clearly dependent on international collaboration. Hopefully, this article will help to inaugurate this process."],["dc.identifier.doi","10.4084/MJHID.2015.034"],["dc.identifier.fs","618516"],["dc.identifier.pmid","25960862"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/13585"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/91971"],["dc.language.iso","en"],["dc.notes.intern","Migrated from goescholar"],["dc.relation.issn","2035-3006"],["dc.relation.orgunit","Universitätsmedizin Göttingen"],["dc.rights","CC BY 2.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/2.0"],["dc.title","Rare cytogenetic abnormalities in myelodysplastic syndromes."],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.subtype","original_ja"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Frontiers in Immunology"],["dc.bibliographiccitation.volume","12"],["dc.contributor.author","Dickel, Steffen"],["dc.contributor.author","Grimm, Clemens"],["dc.contributor.author","Amschler, Katharina"],["dc.contributor.author","Schnitzler, Sebastian Uwe"],["dc.contributor.author","Schanz, Julie"],["dc.contributor.author","Moerer, Onnen"],["dc.contributor.author","Payen, Didier"],["dc.contributor.author","Tampe, Bjoern"],["dc.contributor.author","Winkler, Martin Sebastian"],["dc.date.accessioned","2021-06-01T09:42:24Z"],["dc.date.available","2021-06-01T09:42:24Z"],["dc.date.issued","2021"],["dc.description.abstract","Background The major histocompatibility complex (MHC) class II characterized by monocytes CD14+ expression of human leukocyte antigen receptors (HLA-DR), is essential for the synapse between innate and adaptive immune response in infectious disease. Its reduced expression is associated with a high risk of secondary infections in septic patients and can be safely corrected by Interferon-y (IFNy) injection. Coronavirus disease (COVID-19) induces an alteration of Interferon (IFN) genes expression potentially responsible for the observed low HLA-DR expression in circulating monocytes (mHLA-DR). Methods We report a case of one-time INFy injection (100 mcg s.c.) in a superinfected 61-year-old man with COVID-19–associated acute respiratory distress syndrome (ARDS), with monitoring of mHLA-DR expression and clinical tolerance. Observations Low mHLA-DR pretreatment expression (26.7%) was observed. IFNy therapy leading to a rapid increase in mHLA-DR expression (83.1%). Conclusions Severe ARDS in a COVID-19 patient has a deep reduction in mHLA-DR expression concomitantly with secondary infections. The unique IFNy injection was safe and led to a sharp increase in the expression of mHLA-DR. Based on immune and infection monitoring, more cases of severe COVID-19 patients with low mHLA-DR should be treated by IFNy to test the clinical effectiveness."],["dc.description.sponsorship","Open-Access-Publikationsfonds 2021"],["dc.identifier.doi","10.3389/fimmu.2021.645124"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/17848"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/85242"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-425"],["dc.notes.intern","Merged from goescholar"],["dc.publisher","Frontiers Media S.A."],["dc.relation.eissn","1664-3224"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Case Report: Interferon-γ Restores Monocytic Human Leukocyte Antigen Receptor (mHLA-DR) in Severe COVID-19 With Acquired Immunosuppression Syndrome"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Blood Cancer Journal"],["dc.bibliographiccitation.volume","8"],["dc.contributor.author","Schanz, Julie"],["dc.contributor.author","Cevik, Naciye"],["dc.contributor.author","Fonatsch, Christa"],["dc.contributor.author","Braulke, Friederike"],["dc.contributor.author","Shirneshan, Katayoon"],["dc.contributor.author","Bacher, Ulrike"],["dc.contributor.author","Haase, Detlef"],["dc.date.accessioned","2020-12-10T18:09:40Z"],["dc.date.available","2020-12-10T18:09:40Z"],["dc.date.issued","2018"],["dc.identifier.doi","10.1038/s41408-018-0061-z"],["dc.identifier.eissn","2044-5385"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/15581"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/73724"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.notes.intern","Merged from goescholar"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","Detailed analysis of clonal evolution and cytogenetic evolution patterns in patients with myelodysplastic syndromes (MDS) and related myeloid disorders"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","753849"],["dc.bibliographiccitation.journal","Frontiers in Immunology"],["dc.bibliographiccitation.volume","12"],["dc.contributor.author","Grimm, Clemens"],["dc.contributor.author","Dickel, Steffen"],["dc.contributor.author","Grundmann, Julian"],["dc.contributor.author","Payen, Didier"],["dc.contributor.author","Schanz, Julie"],["dc.contributor.author","Zautner, Andreas Erich"],["dc.contributor.author","Tampe, Björn"],["dc.contributor.author","Moerer, Onnen"],["dc.contributor.author","Winkler, Martin Sebastian"],["dc.date.accessioned","2021-12-01T09:22:40Z"],["dc.date.available","2021-12-01T09:22:40Z"],["dc.date.issued","2021"],["dc.description.abstract","Background CD14+ monocytes present antigens to adaptive immune cells via monocytic human leukocyte antigen receptor (mHLA-DR), which is described as an immunological synapse. Reduced levels of mHLA-DR can display an acquired immune defect, which is often found in sepsis and predisposes for secondary infections and fatal outcomes. Monocytic HLA-DR expression is reliably induced by interferon- γ (IFNγ) therapy. Case Report We report a case of multidrug-resistant superinfected COVID-19 acute respiratory distress syndrome (ARDS) on extracorporeal membrane oxygenation (ECMO) support. The resistance profiles of the detected Klebsiella pneumoniae , Pseudomonas aeruginosa, Acinetobacter baumannii and Citrobacter freundii isolates were equipped with resistance to all four antibiotic classes including carbapenems (4MRGN) and Cefiderocol in the case of K. pneumoniae . A causal therapeutic antibiotic strategy was not available. Therefore, we measured the immune status of the patient aiming to identify a potential acquired immune deficiency. Monocyte HLA-DR expression identified by FACS analysis revealed an expression level of 34% positive monocytes and suggested severe immunosuppression. We indicated IFNγ therapy, which resulted in a rapid increase in mHLA-DR expression (96%), rapid resolution of invasive bloodstream infection, and discharge from the hospital on day 70. Discussion Superinfection is a dangerous complication of COVID-19 pneumonia, and sepsis-induced immunosuppression is a risk factor for it. Immunosuppression is expressed by a disturbed antigen presentation of monocytes to cells of the adaptive immune system. The case presented here is remarkable as no validated antibiotic regimen existed against the detected bacterial pathogens causing bloodstream infection and severe pneumonia in a patient suffering from COVID-19 ARDS. Possible restoration of the patient’s own immunity by IFNγ was a plausible option to boost the patient’s immune system, eliminate the identified 4MRGNs, and allow for lung recovery. This led to the conclusion that immune status monitoring is useful in complicated COVID-19-ARDS and that concomitant IFNγ therapy may support antibiotic strategies. Conclusion After a compromised immune system has been detected by suppressed mHLA-DR levels, the immune system can be safely reactivated by IFNγ."],["dc.description.sponsorship","Open-Access-Publikationsfonds 2021"],["dc.identifier.doi","10.3389/fimmu.2021.753849"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/94458"],["dc.notes.intern","DOI-Import GROB-478"],["dc.relation.eissn","1664-3224"],["dc.rights","CC BY 4.0"],["dc.title","Case Report: Interferon- γ Rescues Monocytic Human Leukocyte Antigen Receptor (mHLA-DR) Function in a COVID-19 Patient With ARDS and Superinfection With Multiple MDR 4MRGN Bacterial Strains"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.subtype","original_ja"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","E179"],["dc.bibliographiccitation.issue","10"],["dc.bibliographiccitation.journal","Haematologica"],["dc.bibliographiccitation.lastpage","E181"],["dc.bibliographiccitation.volume","99"],["dc.contributor.author","Mueller-Thomas, Catharina"],["dc.contributor.author","Rudelius, Martina"],["dc.contributor.author","Rondak, Ina-Christine"],["dc.contributor.author","Haferlach, Torsten"],["dc.contributor.author","Schanz, Julie"],["dc.contributor.author","Huberle, Christina"],["dc.contributor.author","Schmidt, Burkhard C."],["dc.contributor.author","Blaser, Rainer"],["dc.contributor.author","Kremer, Marcus"],["dc.contributor.author","Peschel, Christian"],["dc.contributor.author","Germing, Ulrich"],["dc.contributor.author","Platzbecker, Uwe"],["dc.contributor.author","Goetze, Katharina S."],["dc.date.accessioned","2018-11-07T09:34:28Z"],["dc.date.available","2018-11-07T09:34:28Z"],["dc.date.issued","2014"],["dc.identifier.doi","10.3324/haematol.2014.104760"],["dc.identifier.isi","000343038500002"],["dc.identifier.pmid","24972774"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/14445"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/32174"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Ferrata Storti Foundation"],["dc.relation.issn","0390-6078"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Response to azacitidine is independent of p53 expression in higher-risk myelodysplastic syndromes and secondary acute myeloid leukemia"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.subtype","letter_note"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]